Charles River buys WuXi PharmaTech in $1.6 billion deal

Pharmaceutical research company Charles River pays $1.6 billion in cash and stock to acquire Chinese outsourcing company WuXi PharmaTech two-and-a-half years after its listing in the US.

Charles River Laboratories International, a provider of research models and associated services of preclinical drug development, is to buy US-listed Chinese drug research and development outsourcing company Wuxi PharmaTech in a $1.6 billion cash and stock deal.

The new company will retain the name Charles River and offer an expanded portfolio of products and outsourcing services to multinational pharmaceutical, biotechnology and medical device companies, and to academic and government institutions.

James Foster, chairman, president and chief executive...

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES

  • 2nd Compliance Summit Southeast Asia

    17 August 2017  |  Singapore
    The 2017 Compliance Summit Southeast Asia will take an in-depth look at the key compliance considerations today with a focus on regulation and new ...